Opinion

Video

Episode 1: Advancing Patient Care in Non–Muscle-Invasive Bladder Cancer

Author(s):

Max Kates, MD

A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in patient care while highlighting recent treatment advances that offer promising solutions.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
Related Content
From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance
June 16th 2025

From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance

Anne K. Schuckman, MD Hannah Clarke
Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
June 12th 2025

FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC

Hannah Clarke
The approval is supported by findings from the phase 3 ENVISION trial.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
June 9th 2025

En bloc resection of bladder tumor: Is it the way forward?

Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
Survey: New NMIBC treatments face slow uptake
June 2nd 2025

Survey: New NMIBC treatments face slow uptake

Benjamin P. Saylor
Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
© 2025 MJH Life Sciences

All rights reserved.